Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 323

1.

Syncope after vaccination--United States, January 2005-July 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2008 May 2;57(17):457-60.

2.

Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.

America Academy of Pediatrics Commitee on Infectious Diseases.

Pediatrics. 2006 Mar;117(3):965-78. Epub 2005 Dec 28.

PMID:
16382131
3.

Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).

Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, Mijalski CM, Tiwari T, Weston EJ, Cohn AC, Srivastava PU, Moran JS, Schwartz B, Murphy TV; Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2006 Mar 24;55(RR-3):1-34.

4.

Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2005 Oct 14;54(40):1023-5.

5.

Vaccination coverage among adolescents aged 13-17 years - United States, 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2008 Oct 10;57(40):1100-3. Erratum in: MMWR Morb Mortal Wkly Rep. 2009 Jan 16;58(1):10.

7.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

8.

Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2006 Oct 20;55(41):1120-4. Erratum in: MMWR Morb Mortal Wkly Rep. 2006 Nov 3;55(43):1177.

9.
10.
11.

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group.

Clin Infect Dis. 2009 Jul 1;49(1):e1-10. doi: 10.1086/599117.

PMID:
19476428
12.

FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2009 Apr 17;58(14):374-5.

13.

The preteen visit: an opportunity for prevention.

Campos-Outcalt D.

J Fam Pract. 2006 Dec;55(12):1054-6.

PMID:
17137541
14.
15.

Chorioamnionitis following vaccination in the Vaccine Adverse Event Reporting System.

Datwani H, Moro PL, Harrington T, Broder KR.

Vaccine. 2015 Jun 17;33(27):3110-3. doi: 10.1016/j.vaccine.2015.04.097. Epub 2015 May 11.

PMID:
25976546
16.

Adverse event reporting rates following tetanus-diphtheria and tetanus toxoid vaccinations: data from the Vaccine Adverse Event Reporting System (VAERS), 1991-1997.

Lloyd JC, Haber P, Mootrey GT, Braun MM, Rhodes PH, Chen RT; VAERS Working Group.

Vaccine. 2003 Sep 8;21(25-26):3746-50.

PMID:
12922107
17.

FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9. Erratum in: MMWR Morb Mortal Wkly Rep. 2010 Sep 17;59(36):1184.

18.

FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2011 Sep 23;60(37):1279-80.

19.

Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration.

Weston WM, Friedland LR, Wu X, Howe B.

Vaccine. 2011 Jan 29;29(5):1017-22. doi: 10.1016/j.vaccine.2010.11.057. Epub 2010 Dec 4.

PMID:
21134450
20.

U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007.

Chang S, O'Connor PM, Slade BA, Woo EJ.

Vaccine. 2013 Feb 27;31(10):1447-52. doi: 10.1016/j.vaccine.2012.10.097. Epub 2012 Nov 8.

PMID:
23142308

Supplemental Content

Support Center